These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32546645)

  • 1. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
    Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
    Clin Cancer Res; 2020 Sep; 26(18):4863-4868. PubMed ID: 32546645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.
    George DJ; Martini JF; Staehler M; Motzer RJ; Magheli A; Escudier B; Gerletti P; Li S; Casey M; Laguerre B; Pandha HS; Pantuck AJ; Patel A; Lechuga MJ; Ravaud A
    Clin Cancer Res; 2018 Apr; 24(7):1554-1561. PubMed ID: 29374054
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
    Xu W; Puligandla M; Manola J; Bullock AJ; Tamasauskas D; McDermott DF; Atkins MB; Haas NB; Flaherty K; Uzzo RG; Dutcher JP; DiPaola RS; Bhatt RS
    Clin Cancer Res; 2019 Oct; 25(20):6098-6106. PubMed ID: 31471309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma.
    Mano R; Flynn J; Blum KA; Silagy AW; DiNatale RG; Marcon J; Wang A; Sanchez A; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Urol Oncol; 2019 Dec; 37(12):916-923. PubMed ID: 31590969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
    Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
    J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
    Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
    Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.
    Rini BI; Escudier B; Martini JF; Magheli A; Svedman C; Lopatin M; Knezevic D; Goddard AD; Febbo PG; Li R; Lin X; Valota O; Staehler M; Motzer RJ; Ravaud A
    Clin Cancer Res; 2018 Sep; 24(18):4407-4415. PubMed ID: 29773662
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.
    Sun J; Ning H; Sun J; Qu X
    Urol Oncol; 2016 May; 34(5):239.e9-15. PubMed ID: 26803433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.
    Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
    Future Oncol; 2021 Feb; 17(4):403-409. PubMed ID: 33028084
    [No Abstract]   [Full Text] [Related]  

  • 12. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
    Keizman D; Ish-Shalom M; Huang P; Eisenberger MA; Pili R; Hammers H; Carducci MA
    Eur J Cancer; 2012 Jan; 48(2):202-8. PubMed ID: 22018713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma.
    Sato MT; Ida A; Kanda Y; Takano K; Ohbayashi M; Kohyama N; Morita J; Fuji K; Sasaki H; Ogawa Y; Kogo M
    BMC Cancer; 2022 Nov; 22(1):1214. PubMed ID: 36434552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between age and sex and mortality after adjuvant therapy for renal cancer.
    Mamtani R; Wang XV; Gyawali B; DiPaola RS; Epperson CN; Haas NB; Dutcher JP
    Cancer; 2019 May; 125(10):1637-1644. PubMed ID: 30620389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
    Gross-Goupil M; Kwon TG; Eto M; Ye D; Miyake H; Seo SI; Byun SS; Lee JL; Master V; Jin J; DeBenedetto R; Linke R; Casey M; Rosbrook B; Lechuga M; Valota O; Grande E; Quinn DI
    Ann Oncol; 2018 Dec; 29(12):2371-2378. PubMed ID: 30346481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
    Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Factor in Patients with Non-metastatic Renal Cell Carcinoma.
    Wen RM; Zhang YJ; Ma S; Xu YL; Chen YS; Li HL; Bai J; Zheng JN
    Asian Pac J Cancer Prev; 2015; 16(9):3703-8. PubMed ID: 25987025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.
    George DJ; Martini JF; Staehler M; Motzer RJ; Magheli A; Donskov F; Escudier B; Li S; Casey M; Valota O; Laguerre B; Pantuck AJ; Pandha HS; Patel A; Lechuga M; Ravaud A
    Clin Cancer Res; 2019 Feb; 25(4):1165-1173. PubMed ID: 30401688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.